Emerging as a metabolic longevity therapy
Cardiovascular Outcomes Analysis Major adverse cardiovascular events occurred less frequently than anticipated in both the retatrutide and placebo groups, resulting in relatively few events during the study
Combined with a sleep quality + duration block, this is meaningfully closer to a primary-care intake than the typical compounded-only flow
Baicalin can lower the levels of pro-inflammatory cytokines (e.g., IL-1, IL-2, IL-4, IL-6, IL-17A, and TNF-) and chemokines, by regulating the ratio of different types of B cells (decreasing the ratio of B220 + lymphocytes and increasing the ratio of memory B cells) and inhibiting TGF-1 signaling, associated with fibrosis and immune regulation
enhances fat metabolism and delays age-related decline
From Phase 3 obesity contenders and oral GLP-1 breakthroughs to reframing liver and brain risk, this week reinforces a clear shift: metabolic disease care is becoming broader, earlier, and far more integrated
